Strong Selection Significantly Increases Epistatic Interactions in the Long-Term Evolution of a Protein

TL;DR

This study investigates how strong selection influences epistatic interactions in HIV-1 protease over long-term evolution, revealing that selection increases epistasis, which affects the protein's adaptability and fitness landscape complexity.

Contribution

It provides the first long-term analysis of epistasis evolution in HIV-1 protease, demonstrating that strong selection enhances epistatic interactions over nearly a decade.

Findings

Epistasis continues to increase under strong selection.

Selection-driven epistasis compensates for sequence variability.

HIV-1 protease has not reached its full evolutionary potential.

Abstract

Epistatic interactions between residues determine a protein's adaptability and shape its evolutionary trajectory. When a protein experiences a changed environment, it is under strong selection to find a peak in the new fitness landscape. It has been shown that strong selection increases epistatic interactions as well as the ruggedness of the fitness landscape, but little is known about how the epistatic interactions change under selection in the long-term evolution of a protein. Here we analyze the evolution of epistasis in the protease of the human immunodeficiency virus type 1 (HIV-1) using protease sequences collected for almost a decade from both treated and untreated patients, to understand how epistasis changes and how those changes impact the long-term evolvability of a protein. We use an information-theoretic proxy for epistasis that quantifies the co-variation between sites, and show that positive information is a necessary (but not sufficient) condition that detects epistasis in most cases. We analyze the "fossils" of the evolutionary trajectories of the protein contained in the sequence data, and show that epistasis continues to enrich under strong selection, but not for proteins whose environment is unchanged. The increase in epistasis compensates for the information loss due to sequence variability brought about by treatment, and facilitates adaptation in the increasingly rugged fitness landscape of treatment. While epistasis is thought to enhance evolvability via valley-crossing early-on in adaptation, it can hinder adaptation later when the landscape has turned rugged. However, we find no evidence that the HIV-1 protease has reached its potential for evolution after 9 years of adapting to a drug environment that itself is constantly changing.